MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating)'s stock price dropped 0.4% during trading on Wednesday . The stock traded as low as $2.50 and last traded at $2.51. Approximately 7,858 shares traded hands during mid-day trading, a decline of 95% from the average daily volume of 169,116 shares. The stock had previously closed at $2.52.
Analysts Set New Price Targets
Separately, HC Wainwright initiated coverage on shares of MiNK Therapeutics in a research note on Wednesday, August 10th. They issued a "buy" rating and a $7.00 price target for the company.
Get
MiNK Therapeutics alerts:
MiNK Therapeutics Price Performance
The business's 50 day moving average is $2.34 and its 200 day moving average is $2.02. The stock has a market cap of $84.80 million, a price-to-earnings ratio of -3.22 and a beta of -0.63.
MiNK Therapeutics (NASDAQ:INKT – Get Rating) last issued its earnings results on Thursday, November 3rd. The company reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.04. As a group, analysts forecast that MiNK Therapeutics, Inc. will post -0.84 earnings per share for the current year.
Hedge Funds Weigh In On MiNK Therapeutics
A hedge fund recently bought a new stake in MiNK Therapeutics stock. First Republic Investment Management Inc. bought a new position in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 81,500 shares of the company's stock, valued at approximately $172,000. First Republic Investment Management Inc. owned approximately 0.24% of MiNK Therapeutics at the end of the most recent quarter. 1.07% of the stock is currently owned by institutional investors.
About MiNK Therapeutics
(Get Rating)
MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials.
Read More
- Get a free copy of the StockNews.com research report on MiNK Therapeutics (INKT)
- The Question of a Fed Pivot Isn't If, It's When, Here's Why
- Top 10 Searched Stocks on MarketBeat All-Access
- 3 Dividend Kings With Royally Good Upside
- Institutions Sell The Rallies In Toll Brothers Stock
- Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
